Marriage Counselors in Julian, CA Accepting Medicare
4 Marriage Counselors found. Showing 1 - 4
 Mrs. Krystin R Hunter Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1704 Cape Horn Ave, Julian, CA 92036 Phone: 760-765-2228 |
Meredith Page Brooks, AMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 35072 Big Pine Ln, Julian, CA 92036 Phone: 760-390-2905 |
Ms. Jennifer Suzanne Roberts, MFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 2907 Washington Street, Ste B, Julian, CA 92036 Phone: 760-533-9049 |
Kypris Aster Drake, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 2811 A Street, Julian, CA 92036 Phone: 760-522-2554 |
News Archive
Shire and Parion Sciences to collaborate on P-321 for ophthalmic indications
Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.
New programme to reduce risk of type 2 diabetes in people with schizophrenia
A group of researchers, led by Professor Richard Holt at the University of Southampton, are to investigate whether people with schizophrenia or first episode psychosis are able to reduce their weight through a structured education programme.
Patients with early, severe depression symptoms have increased genetic risk for psychiatric disorders
Clinical features of major depressive disorder (MDD) may help identify specific subgroups of depressed patients based on associations with genetic risk for major psychiatric disorders, reports a study in Biological Psychiatry.
Columbia Laboratories shareholders approve Watson's aquisition terms
Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that shareholders of Columbia Laboratories, Inc. (Nasdaq: CBRX) have approved the terms and conditions of the previously announced acquisition by Watson of the U.S. rights to Columbia's CRINONE® and PROCHIEVE® progesterone gel product line and 11,200,000 shares of Columbia common stock.
› Verified 5 days ago